Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473004 · ClinicalTrials.gov registry record · Phase 2
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
A Phase 2 study of Stage IV Uveal Melanoma, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT01473004 is a Phase 2 study of Stage IV Uveal Melanoma that has completed, run by Thomas Jefferson University. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01473004, a Phase 2 study of Stage IV Uveal Melanoma, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die. This is a phase II clinical trial to investigate safety and efficacy of radioactive microsphere (SIR-Spheres® microspheres). Uveal melanoma patients with progressing hepatic metastases who received no more than one intra-hepatic arterial treatment will be enrolled. Patients will be first stratified into two groups: Group A, no prior intra-hepatic arterial treatment; Group B, one prior intra-hepatic arterial treatment).
Conditions Studied
Interventions
- DEVICE Sir-Spheres®
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-10-31 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473004
The ClinicalTrials.gov registry entry for NCT01473004 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IV Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Sir-Spheres® is the first listed.
NCT01473004 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01473004 about?
NCT01473004 is a clinical study titled "SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver". The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die. This is a phase II clinical trial to investigate safety and efficacy of radioactive ...
What is the current status of trial NCT01473004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2011-10-31. Estimated completion is 2024-12-31.
What conditions does trial NCT01473004 study?
This clinical trial studies the following conditions: Stage IV Uveal Melanoma.
What interventions are being tested in trial NCT01473004?
The interventions under investigation include: Sir-Spheres® (DEVICE).
Who is sponsoring clinical trial NCT01473004?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01473004 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.